Loading news...
Billiontoone (NASDAQ: BLLN - Get Free Report) and Caris Life Sciences (NASDAQ: CAI - Get Free Report) are both mid-cap services companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation. Valuation and Earnings This table compares Billiontoone
Caris Life Sciences (NASDAQ: CAI - Get Free Report) and Billiontoone (NASDAQ: BLLN - Get Free Report) are both mid-cap services companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation. Analyst Recommendations This is a summary of
Caris Life Sciences (NASDAQ: CAI - Get Free Report) and Billiontoone (NASDAQ: BLLN - Get Free Report) are both mid-cap services companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership. Analyst Recommendations This is a breakdown of
Exploring Baillie Gifford (Trades, Portfolio)'s Fourth Quarter 2025 Investment Adjustments Baillie Gifford (Trades, Portfolio) recently submitted the 13F filin
Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine brokerages that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price
Integration enables seamless ordering and results delivery within Epic for UNITY Complete® and Northstar® tests, creating a better patient and provider experience MENLO PARK, Calif., Jan. 15, 2026 /PRNewswire/ -- BillionToOne , Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced a collaboration with Epic , the nation's most widely used comprehensive electronic health record (EHR).
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full year 2026 guidance.
Ultra-sensitive liquid biopsy is expanding precision medicine access for patients in Japan with treatment-resistant non-small cell lung cancer (NSCLC) MENLO PARK, Calif., Jan. 6, 2026 /PRNewswire/ -- BillionToOne , Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the selection of Northstar Select ® as the new liquid biopsy in LC-SCRUM-TRY- Japan, a nationwide, multi-center study to better elucidate the mechanisms of drug resistance and the characteristics of drug-resistant lung cancer.
MENLO PARK, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the 44th Annual J.P. Morgan Healthcare Conference.
BillionToOne, Inc. ( BLLN ) Q3 2025 Earnings Call December 9, 2025 4:30 PM EST Company Participants David Deichler Oguzhan Atay - Co-Founder, Chairman & CEO Ross Taylor - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG, LLC, Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division David Westenberg - Piper Sandler & Co., Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Presentation Operator BillionToOne Third Quarter 2025 Earnings Call.
MENLO PARK, Calif. , Dec. 9, 2025 /PRNewswire/ – BillionToOne , Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026.
MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2025 and initiated guidance for the remainder of 2025.
MENLO PARK, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for third quarter ended September 30, 2025 after the market close on Tuesday, December 9, 2025. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
BillionToOne, Inc., (NASDAQ: BLLN) recently completed an upsized initial public offering, or IPO, of 5.23 million shares at $60 each, raising roughly $314 million.
Wall Street analysts, who acted as lead underwriters for BillionToOne's Nasdaq debut last month, began coverage of the diagnostics firm on Monday with broadly upbeat views, pointing to its advanced technology and growth prospects in prenatal and cancer testing.
Cancer stock BillionToOne has formed an IPO base with a buy point of 123.84. The company provides cancer diagnostic tools.
BillionToOne leverages groundbreaking molecular diagnostics technology, targeting massive prenatal and oncology testing markets with rapid revenue growth. Revenues more than doubled to $152 million in 2024, with growth continuing at such percentages while operating profits are reported here. Valuation stands at 15 times annualised sales, justified by accelerating growth and improving margins, but revenue concentration and competition pose risks.
REDWOOD CITY, Calif. , Nov. 6, 2025 /PRNewswire/ -- Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, a leading law firm in technology and life sciences transactions, represented long-time client BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company on a mission to make powerful and accessible genetic tests available to all, in its upsized initial public offering of 4.6 million shares of Class A common stock at a price to the public of $60 per share, generating approximately $273.1 million in aggregate gross proceeds.
Shares of BillionToOne rose 66.67% in their Nasdaq debut on Thursday, valuing the molecular diagnostics firm at $4.4 billion.
Molecular diagnostics firm BillionToOne raised $273.1 million in its U.S. initial public offering on Wednesday, pricing its shares above its marketed range.